Last updated: February 20, 2026
What is the Product?
NDC 69452-0289 corresponds to Vabysmo (faricimab-svoa), a drug developed by Roche for the treatment of age-related macular degeneration (AMD) and diabetic macular edema (DME). Approved by the FDA in January 2022, Vabysmo is the first bispecific antibody for ophthalmic use targeting both angiopoietin-2 and VEGF-A pathways.
Market Overview
Market Size and Growth
The ophthalmic anti-VEGF market was valued at approximately $8.2 billion in 2022, with a compound annual growth rate (CAGR) of 5.1% projected through 2027. Key drivers include the increasing prevalence of AMD and DME in aging populations and limited treatment options.
| Year |
Market Size (USD Billion) |
CAGR (%) |
| 2022 |
8.2 |
- |
| 2023 |
8.6 |
5.0 |
| 2024 |
9.0 |
4.9 |
| 2025 |
9.5 |
5.0 |
| 2027 |
10.5 |
5.1 |
Competitive Landscape
Main competitors include:
- Eylea (aflibercept, Regeneron/Bayer)
- Lucentis (ranibizumab, Genentech)
- Beovu (brolucizumab, Bausch + Lomb)
- Susvimo (port delivery system for ranibizumab)
Vabysmo introduces a bispecific mechanism, targeting both pathways simultaneously, which may offer longer dosing intervals and improved efficacy, potentially gaining market share from established drugs.
Market Penetration and Adoption
As a new entrant, Vabysmo's rollout is in early stages. Adoption depends on:
- Clinical trial results showing non-inferiority or superiority
- Regulatory approvals in other markets (EU, Japan)
- Physician and patient acceptance of dosing intervals
Initial launch strategies involve targeting high-volume retinal centers, with expansion over the next 12-24 months.
Price Data and Projections
Current Pricing
The average wholesale acquisition cost (AWAC) of Vabysmo is approximately $2,100 per injection, aligning with other anti-VEGF therapies:
| Drug |
AWAC per injection |
Dosing regimens |
| Vabysmo |
$2,100 |
Initially monthly, then every 8-12 weeks after loading dose |
| Eylea |
$2,000 |
Monthly initially, then every 8-12 weeks |
| Lucentis |
$2,100 |
Monthly for first 3 months, then every 4-8 weeks |
Price Trends
- Prices for anti-VEGF agents tend to stabilize post-launch with slight variations based on negotiations and rebates.
- Vabysmo's pricing is aimed to be competitive with existing therapies.
- Future price reductions may occur due to competition, biosimilar entrance, or formulary negotiations, potentially reducing procurement costs by 10-20% over the next 3-5 years.
Revenue Projections
Assuming a conservative market share capture of 10% within the first 2 years, with pricing maintained at $2,100 per injection, revenues are projected as follows:
| Year |
Analyzed Market Size (USD Billion) |
Vabysmo Market Share |
Estimated Annual Revenue (USD Millions) |
| 2022 |
8.2 |
0% |
$0 |
| 2023 |
8.6 |
2% |
~$45 |
| 2024 |
9.0 |
5% |
~$94 |
| 2025 |
9.5 |
10% |
~$188 |
| 2027 |
10.5 |
15% |
~$330 |
This assumes approximately 200,000 annual treatment courses globally by 2025, with incremental growth in patient acceptance.
Pricing Strategies and Market Risks
- Use of performance-based pricing or rebates could reduce net revenue.
- Biosimilar competition starting 2025-2026 may put downward pressure.
- Variations in reimbursement policies across regions impact net pricing.
Regulatory and Commercial Outlook
- Additional EU approval expected in 2024.
- Japan submission targeted for late 2023.
- Market penetration depends on clinical trial outcomes and real-world effectiveness data.
Key Takeaways
- Vabysmo enters a mature market with a well-established competitor landscape.
- The product's bispecific mechanism affords potential advantages, but its long-term market share depends on clinical performance and physician acceptance.
- Current pricing aligns with existing therapies; future reductions expected due to biosimilar and generic pressure.
- Revenue projections indicate slow but steady growth through 2027, contingent on market penetration.
FAQs
What factors influence Vabysmo's price stability?
Reimbursement negotiation, competitive pricing, biosimilar entry, and formulary placements.
How does Vabysmo's mechanism differentiate it?
It targets both angiopoietin-2 and VEGF-A pathways, potentially enabling extended dosing intervals and improved outcomes.
What is the timeline for market expansion?
EU approval anticipated in 2024; additional markets like Japan targeted for late 2023-2024.
What are the risks to revenue growth?
Slowing market penetration, biosimilar competition, regulatory delays, or unfavorable reimbursement policies.
How sensitive are projections to pricing changes?
A 10% reduction in per-injection price could decrease estimated revenue by approximately $19 million annually by 2025.
References
[1] Grand View Research. (2022). Ophthalmic Anti-VEGF Market Size, Share & Trends Analysis. Retrieved from https://www.grandviewresearch.com/industry-analysis/ophthalmic-anti-vegf-market
[2] U.S. Food and Drug Administration. (2022). Vabysmo (faricimab-svoa) approval announcement. Retrieved from https://www.fda.gov/drugs/resources-information-approved-drugs/vabysmo-approved-treatment-neovascular-age-related-macular-degeneration-disease
[3] IQVIA. (2023). Global Ophthalmic Drugs Market Analysis. Retrieved from https://www.iqvia.com/solutions/analytics/market-analysis
